ORIGINAL PAPER
Oxidative stress markers are increased in non-alcoholic fatty liver disease patients with high serum alanine aminotransferase levels
1
Department of Medical Biochemistry, Institute of Health Sciences, Gazi University, Ankara, Turkey
2
Department of Medical Biochemistry, Medical Faculty, Ufuk University, Ankara, Turkey
3
Division of Gastroenterology, Department of Internal Medicine, Istanbul Medipol University, Istanbul, Turkey
4
Department of Biochemistry, Faculty of Pharmacy, Zonguldak Bulent Ecevit University, Zonguldak, Turkey
Submission date: 2019-08-29
Final revision date: 2019-10-22
Acceptance date: 2019-11-14
Publication date: 2019-12-30
Medical Studies 2019;35(4):283-287
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Non-alcoholic fatty liver disease (NAFLD) is a pathological disease that causes chronic damage in the liver without alcohol consumption.
Aim of the research:
To determine oxidative stress and inflammation statuses (NAFLD) with increased alanine aminotransferase (ALT).
Material and methods:
Oxidative stress (malondialdehyde (MDA), advanced oxidation protein products (AOPP), inflammation (serum tumour necrosis factor-α (TNF-α)), interleukin-6 (IL-6), and hyaluronic acid (HA) were measured by the ELISA method or manually. A total of 133 non-obese and non-diabetic individuals were included. Patients diagnosed with NAFLD with normal ALT levels were included in group 1 (n = 53), and those with high ALT levels were included in group 2 (n = 35). The control group included individuals without any known systemic disease (n = 45).
Results:
We found that the serum MDA levels were significantly elevated in group 2 in comparison to the control group (p < 0.05). However, there were no significant changes in the serum AOPP levels in any group (p > 0.05). The serum TNF-α and IL-6 levels of group 1 and group 2 were higher than those in the control group (p < 0.05). The serum HA levels in group 2 increased significantly in comparison to the other groups (p < 0.05).
Conclusions:
HA and MDA were enhanced with high ALT levels and with elevated TNF-α and IL-6 levels without high ALT levels in NAFLD.
Non-alcoholic fatty liver disease (NAFLD) is a pathological disease that causes chronic damage in the liver without alcohol consumption.
Aim of the research:
To determine oxidative stress and inflammation statuses (NAFLD) with increased alanine aminotransferase (ALT).
Material and methods:
Oxidative stress (malondialdehyde (MDA), advanced oxidation protein products (AOPP), inflammation (serum tumour necrosis factor-α (TNF-α)), interleukin-6 (IL-6), and hyaluronic acid (HA) were measured by the ELISA method or manually. A total of 133 non-obese and non-diabetic individuals were included. Patients diagnosed with NAFLD with normal ALT levels were included in group 1 (n = 53), and those with high ALT levels were included in group 2 (n = 35). The control group included individuals without any known systemic disease (n = 45).
Results:
We found that the serum MDA levels were significantly elevated in group 2 in comparison to the control group (p < 0.05). However, there were no significant changes in the serum AOPP levels in any group (p > 0.05). The serum TNF-α and IL-6 levels of group 1 and group 2 were higher than those in the control group (p < 0.05). The serum HA levels in group 2 increased significantly in comparison to the other groups (p < 0.05).
Conclusions:
HA and MDA were enhanced with high ALT levels and with elevated TNF-α and IL-6 levels without high ALT levels in NAFLD.
REFERENCES (32)
1.
Fiorucci S, Biagioli M, Distrutti E. Future trends in the treatment of non-alcoholic steatohepatitis. Pharmacol Res 2018; 134: 289-298.
2.
Del Ben M, Polimeni L, Baratta F, Pastori D, Angelico F. The role of nutraceuticals for the treatment of non-alcoholic fatty liver disease. Br J Clin Pharmacol 2017; 83: 88-95.
4.
Tolman KG, Fonseca V, Ton MH, Dalplaz A. Narrative review: hepatobiliary disease in type 2 diabetes mellitus. Ann Intern Med 2004; 141: 946-956.
5.
Bellanti F, Villani R, Facciorusso A, Vendemiale G, Serviddio G. Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis. Free Radic Biol Med 2017; 111: 173-185.
6.
Cristani M, Speciale A, Saija A, Gangemi S, Minciullo PL, Cimino F. Circulating advanced oxidation protein products as oxidative stress biomarkers and progression mediators in pathological conditions related to inflammation and immune dysregulation. Curr Med Chem 2016; 23: 3862-3882.
7.
Spahis S, Delvin E, Borys JM, Levy E. Oxidative stress as a critical factor in nonalcoholic fatty liver disease pathogenesis. Antioxid Redox Signal 2017; 26: 519-541.
8.
Gudowska M, Cylwik B, Chrostek L. The role of serum hyaluronic acid determination in the diagnosis of liver fibrosis. Acta Biochim Pol 2017; 64: 451-457.
9.
Dludla PV, Nkambule BB, Jack B, Mkandla Z, Mutize T, Silvestri S, Orlando P, Tiano L, Louw J, Mazibuko-Mbe-.
10.
je SE. Inflammation and oxidative stress in an obese state and the protective effects of gallic acid. Nutrients 2018; 11: pii: E23.
11.
Mauer J, Chaurasia B, Goldau J, Vogt MC, Ruud J, Nguyen KD, Theurich S, Hausen AC, Schmitz J, Brönneke HS, Estevez E, Allen TL, Mesaros A, Partridge L, Febbraio MA, Chawla A, Wunderlich FT, Brüning JC. Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin. Nat Immunol 2014; 15: 423-430.
12.
Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43 (2 Suppl 1):.
14.
Suliga E, Kozieł D, Cieśla E, Rębak D, Głuszek S. Dietary patterns in relation to metabolic syndrome among adults in poland: a cross-sectional study. Nutrients 2017; 9: pii: E1366.
15.
Suliga E, Kozieł D, Cieśla E, Rębak D, Głuszek S. Coffee consumption and the occurrence and intensity of metabolic syndrome: a cross-sectional study. Int J Food Sci Nutr 2017; 68: 507-513.
16.
Ashtari S, Pourhoseingholi MA, Zali MR. Non-alcohol fatty liver disease in Asia: prevention and planning. World.
18.
Kontogianni MD, Tileli N, Margariti A, Georgoulis M, Deutsch M, Tiniakos D, Fragopoulou E, Zafiropoulou R, Manios Y, Papatheodoridis G. Adherence to the Mediterranean diet is associated with the severity of non-alcoholic fatty liver disease. Clin Nutr 2014; 33: 678-683.
19.
Shahroukh HD, Davoodi M, Rahmani O, Roushanaei A, Seydeyan SM, Adel SMH. Association of nonalcoholic fatty liver with carotid intima-media thickness in patients with dyslipidaemia. Med Stud 2018; 34: 226-231.
20.
Koo SH. Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis. Clin Mol Hepatol 2013; 19: 210-215.
21.
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73-84.
22.
Ghamar-Chehreh ME, Amini M, Khedmat H, Moayed Alavian S, Daraei F, Mohtashami R, Hadi R, Beyram BA, Taheri S. Elevated alanine aminotransferase activity is not associated with dyslipidemias, but related to insulin resistance and higher disease grades in non-diabetic non-alcoholic fatty liver disease. Asian Pac J Trop Biomed 2012; 2: 702-706.
23.
Orasan OH, Ciulei G, Cozma A, Sava M, Dumitrascu DL. Hyaluronic acid as a biomarker of fibrosis in chronic liver diseases of different etiologies. Clujul Med 2016; 89: 24-31.
24.
Suzuki A, Angulo P, Lymp J, Li D, Satomura S, Lindor K. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. Liver Int 2005; 25: 779-786.
25.
Pawitpok C, Kongtawelert P, Ua-arayaporn S, Punyarit P, Piyanirun W, Chutaputti A. Efficacy of serum hyaluronic acid level for predicting liver fibrosis in patients with nonalcoholic fatty liver disease. Thai J Gastroenterol 2006; 7: 83-87.
26.
Loguercio C, De Simone T, D’Auria MV, de Sio I, Federico A, Tuccillo C, Abbatecola AM, Del Vecchio Blanco C. Non-alcoholic fatty liver disease: a multicentre clinical study by the Italian Association for the Study of the Liver. Dig Liver Dis 2004; 36: 398-405.
27.
Jiang W, Wu N, Wang X, Chi Y, Zhang Y, Qiu X, Hu Y, Li J, Liu Y. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. Sci Rep 2015; 5: 8096.
28.
Wong VW, Wong GL, Choi PC, Chan AW, Li MK, Chan HY. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 2010; 59: 969-974.
29.
Araya J, Rodrigo R, Videla LA, Thielemann L, Orellana M, Pettinelli P, Poniachik J. Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci 2004; 106: 635-643.
30.
Kumar R, Prakash S, Chhabra S, Singla V, Madan K, Gupta SD. Association of pro-inflammatory cytokines, adipokines and oxidative stress with insulin resistance and non-alcoholic fatty liver disease. Indian J Med Res 2012; 136: 229-236.
31.
Mousavi SN, Faghihi A, Motaghinejad M, Shiasi M, Imanparast F, Amiri HL, Shidfar F. Zinc and selenium co-supplementation reduces some lipid peroxidation and angiogenesis markers in a rat model of NAFLD-Fed high fat diet. Biol Trace Elem Res 2018; 181: 288-295.
32.
Videla LA, Rodrigo R, Orellana M, Fernandez V, Tapia G, Quińones L, Varela N, Contreras J, Lazarte R, Csendes A, Rojas J, Maluenda F, Burdiles P, Diaz JC, Smok G, Thielemann L, Poniachik J. Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients. Clin Sci 2004; 106: 261-268.
Share
RELATED ARTICLE
| eISSN: | 2300-6722 |
| ISSN: | 1899-1874 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
